<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3389/fpsyg.2022.861643</dc:identifier><dc:language>eng</dc:language><dc:creator>Lear-Claveras, Ana</dc:creator><dc:creator>Clavería, Ana</dc:creator><dc:creator>Couso-Viana, Sabela</dc:creator><dc:creator>Nabbe, Patrice</dc:creator><dc:creator>Oliván-Blázquez, Bárbara</dc:creator><dc:title>Analysis of Drug and Health Resource Use Before and After COVID-19 Lockdown in a Population Undergoing Treatment for Depression or Anxiety</dc:title><dc:identifier>ART-2022-131273</dc:identifier><dc:description>IntroductionThe arrival of the COVID-19 pandemic modified the functions of Primary Care (PC) teams, which were forced to focus their resources on the diagnosis and treatment of SARS-CoV-2 infected patients. The disrupted healthcare of individuals with pre-existing mental disorders (depression or anxiety), as well as the psychological decompensation resulting from the lockdown caused by the COVID-19 pandemic, may have modified the use of drugs and health resources by these patients. The aim of this study is to determine the changes in these parameters, between the 6 months prior to the lockdown (09/14/2019 to 03/15/2020) and the 6 months following its end (05/03/2020 to 11/04/2020), in a population undergoing active treatment for depression or anxiety, according to the electronic clinical record.Materials and MethodsReal world data observational study of 110,694 individuals aged &amp;amp;gt;16 years suffering from active or undergoing treatment for depression or anxiety according to the electronic medical records of the Aragon Regional Health Service (Spain). Pharmacological variables [daily dose per inhabitant (DHD) dispensed by pharmacies of: anxiolytics, hypnotics/sedatives, and antidepressants] and variables related to the use of healthcare resources (number of primary and specialized healthcare visits) were considered. Student’s T-tests for paired samples were performed to analyze differences between periods (pre–post). The level of significance was established at 5% (p &amp;amp;lt; 0.05).ResultsThe use of anxiolytic drugs increased as compared to its use over the 6 months prior to the lockdown. In contrast, the consumption of antidepressants was found to decrease. The use of health resources continued to be below pre-pandemic levels, 6 months post-lockdown end.ConclusionChanges in the use of health resources could have a negative impact on the parameters of these diseases. The increase in drug use, especially benzodiazepines, may suggest a worsening of the symptoms during the lockdown and in the subsequent months. It is a worrying sign, which points to the growth of this public health problem and the need for its prevention.</dc:description><dc:date>2022</dc:date><dc:source>http://zaguan.unizar.es/record/120958</dc:source><dc:doi>10.3389/fpsyg.2022.861643</dc:doi><dc:identifier>http://zaguan.unizar.es/record/120958</dc:identifier><dc:identifier>oai:zaguan.unizar.es:120958</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA/B21-20R-GAIAP</dc:relation><dc:identifier.citation>Frontiers in Psychology 13 (2022), 861643 [8 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>